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Background: General recommendations for a reference case for economic studies in rheumatic diseases
were published in 2002 in an initiative to improve the comparability of cost-effectiveness studies in the
field. Since then, economic evaluations in osteoarthritis (OA) continue to show considerable hetero-
geneity in methodological approach.
Objectives: To develop a reference case specific for economic studies in OA, including the standard
optimal care, with which to judge new pharmacologic and non-pharmacologic interventions.
Methods: Four subgroups of an ESCEO expert working group on economic assessments (13 experts
representing diverse aspects of clinical research and/or economic evaluations) were charged with producing
lists of recommendations that would potentially improve the comparability of economic analyses in OA:
outcome measures, comparators, costs and methodology. These proposals were discussed and refined during
a face-to-face meeting in 2013. They are presented here in the format of the recommendations of the recently
published Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, so that an
initiative on economic analysis methodology might be consolidated with an initiative on reporting standards.
Results: Overall, three distinct reference cases are proposed, one for each hand, knee and hip OA; with
diagnostic variations in the first two, giving rise to different treatment options: interphalangeal or thumb-
based disease for hand OA and the presence or absence of joint malalignment for knee OA. A set of
management strategies is proposed, which should be further evaluated to help establish a consensus on the
“standard optimal care” in each proposed reference case. The recommendations on outcome measures, cost
itemisation and methodological approaches are also provided.
Conclusions: The ESCEO group proposes a set of disease-specific recommendations on the conduct and
reporting of economic evaluations in OA that could help the standardisation and comparability of studies that
evaluate therapeutic strategies of OA in terms of costs and effectiveness.
& 2014 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Osteoarthritis (OA) is a progressive and painful chronic disease
affecting mainly the hand, knee and/or hip joints. OA has been
shown to be associated with high costs, both in terms of direct
health-related costs (long-term treatments for pain control, surgery
and rehabilitation) and indirect costs (productivity losses) [1–5].
Since no structure-modifying treatments (excepting surgical inter-
ventions) are yet approved in the major regulatory jurisdictions,
the current management strategies are intended to provide symp-
tomatic improvement, using a combination of pharmacological and
non-pharmacological approaches [6–12]. The costs of such strat-
egies and their long-term success are uncertain and often difficult
to compare between studies.
Economic evaluations of disease management options provide
essential information with which to guide efficient resource alloca-
tion in health care, and many countries now have formal require-
ments for an economic evaluation of new pharmaceutical products at
the time of market authorisation [13]. An objective economic
comparison of existing therapeutic strategies in OA is essential for
both the efficient management of the disease and the development
of new treatments and management programmes. Economic evalua-
tions can be complex, with important choices to be made in the
definition of the clinical pathway, the selection of outcome measures,
the most relevant comparator(s) and the accounting of resource
utilisation. The diversity engendered by such decisions as well as a
less-than-transparent reporting of methods in the literature give rise
to substantial difficulties when it comes to comparing studies of
different treatment modalities [14–16]. The efforts to tackle this
problem have come from the following two directions: (a) the
creation of methodological guidelines designed to help investigators
with study/model design and the selection of standardised methods
and (b) the creation of checklists for the reporting of studies, with the
goal of ensuring that all the relevant information pertinent to the
interpretation of a study is present at publication.
A recent article under the auspices of the European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis(ESCEO) concluded that in the field of OA, there was a need to
define a reference case and a consensus on what constitutes
“standard optimal care” in terms of best clinical practice (accord-
ing to the stage and affected joint) that could serve as a com-
parator for more experimental interventions, thus providing a
standard between studies in the same clinical situation [15], while
at the same time allowing flexibility to tailor treatments to the
diversity of the disease condition. The present article presents the
conclusions of discussions on this subject that were held during a
subsequent expert working group meeting, in September 2013,
and outlines the tasks that still need to be done to reach this goal.
The discussions focussed specifically on cost-effectiveness and
comparative economic evaluation; the methodology for evaluating
the burden of disease was not discussed.
Definitions
Reference case: A set of methodological choices for a range of
items relevant to conducting an economic evaluation that
frame the boundaries of the study, such as model horizon,
outcome measure(s), resource use and costing.
Base case: Generally used in the context of modelling, the base
case defines the most plausible values for the relevant
parameters. Departure from the base case may be sensitivity
analyses (varying the values of a parameter) or a scenario
analysis (variation in technology, model structure and/or
clinical pathway).
Subgroups of interest: Patient subgroups that have a risk factor
that may or may not invoke an adaptation of initial standard
treatment, but which may alter the rate of progression, the
risk of complications or response to treatment.
The case for a reference case
The term “reference case”was first coined by the Panel on Cost-
Effectiveness in Health and Medicine, set up by the US Public
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heterogeneity was to define a set of minimal criteria that all
economic analyses should include. The main points were that all
resource consumption associated with an intervention (including
non-health impacts) should be captured, that the health effects of
an intervention should be incorporated into quality-adjusted life
years (QALYs), that costs and health outcomes in the future should
be discounted to present values, that sensitivity analyses should be
used to address uncertainty and that studies should be reported in
a standardised way.
The reference case idea was subsequently taken up by Gabriel
et al. [18] in the OMERACT (Outcome Measures in Rheumatology)
economics working group with the objective of defining a “core
set” of disease-specific parameters for economic evaluations in
rheumatology. Following a set of preliminary recommendations on
methodological issues, which they saw as “controversial,” a con-
sensus set was developed for rheumatoid arthritis (RA) [19,20].
Further discussion for OA, however, left some issues unresolved
[21]. More recently, a reference case for ankylosing spondylitis was
published [22], as was a reference case for modelling in osteopo-
rosis [23].
A number of general guidelines and recommendations for
the design and conduct of cost-effectiveness analyses have appea-
red in the last decade and of particular note is the series of Good
Research Practices published by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) [24–28].
Although these guidelines have not explicitly endorsed the
reference case approach, they have retained the principles sum-
marised above and have helped foster a degree of concordance in
methodology that has helped improve inter-study comparabi-
lity. In an editorial in 2006, Lyles [29] regretted that few cost-
effectiveness analysis (CEA) studies could be found in a MEDLINE
search using the term “reference case” and that considerable
heterogeneity continued to exist. This is still true but, although
not labelled as such, the reference case approach has been largely
accepted by the health care economics community since it
guarantees standardisation without stifling methodological devel-
opment [30].
In parallel to the good research practice recommendations,
numerous reporting checklists have been produced with the aim
of harmonising the presentation of information and thus raising
the quality standard of CEA research articles. The most recent
addition is the ISPOR-backed Consolidated Health Economic Eval-
uation Reporting Standards (CHEERS) statement [31] that proposes
a checklist of 24 items, each with a corresponding recommenda-
tion. This checklist was produced using an approach consistent
with that used for producing the CONSORT statement for reporting
randomised controlled trials (RCTs) (www.consort-statement.org),
which has achieved widespread recognition and acceptance
[32,33]. The aim of this report was to enhance the interpretability
of comparative effectiveness research in osteoarthritis, by propos-
ing a reference case scenario for each of the main manifestations of
the disease (the hand, knee and hip).Methods
Four subgroups of the ESCEO working group on economic
assessments were formed, focusing on comparators, outcomes,
costs and methods. These comprised 5–6 experts each for a total
of 13 individuals [N. Arden, M. Boers, A. Boonen, ML. Brandi,
C. Cooper, M. Drummond, F. Guilleminn, M. Hiligsmannn,
M. Hochbergn, D. Hunter, D. Pinto, J.L. Severens, and P. Tugwelln
(n denotes sub-group leaders)], representing diverse aspects of
clinical research and/or economic evaluations. Each subgroup
prepared a list of the most important topics based on theirreview of the literature and then made a set of preliminary
recommendations. The subsequent step was a face-to-face
meeting for the whole group to make amendments and discuss
further recommendations. The recently published CHEERS state-
ment [31] was taken as a platform on which the group's
recommendations could be presented so as to provide the
maximum coherence.Results
Recommendations of additional text are suggested for eight
items judged most sensitive to disease-specific choices and these
are provided in Table 1 alongside the CHEERS statement. All items
of the CHEERS statement are reproduced, along with the addi-
tional guidance as indicated. Additionally, text is proposed for the
introduction, and the creation of a new item “study design” (as in
CONSORT list) is recommended. This new item is numbered as
item 3, following the merging of items 1 and 2 (title and abstract),
as in CONSORT, and the renumbering of the introduction as item 2.
Furthermore, it was suggested that item 11 (which included
certain aspects of study design) be modified to “measurement of
clinical effectiveness or harms.”
These additions and modifications are explained in the accom-
panying text (below) and, where relevant, an example of good
reporting for the item is provided. Thus, the suggestions in this
article should be seen as additional to the general guidance in the
CHEERS explanatory article [34].Introduction (item no. 2)
CHEERS provide an explicit statement of the broader context for
the study. Present the study question and its relevance for health
policy or practice decisions.
Modification for economic evaluations in general: Frame the
research question using evidence-based practice methodology,
e.g., the GRADE 2 guideline: Framing the question and deciding
on important outcomes and using the Population, Intervention,
Comparator and Outcome (PICO) process.
Example: “In patients (age range, sex…) with symptomatic knee
OA, how does a topical NSAID compare with an oral NSAID for
costs and outcomes for equivalent pain control over the short-
term in out-patients in the context of the UK National Health
Service?”
Explanation: It was considered particularly helpful, to both
investigators and readers, to clearly frame the clinical research
questions using evidence-based practice methodology. A useful
guideline in this respect is the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) number 2:
Framing the question and deciding on important outcomes [35]. As
a part of this process, the guideline recommends using the PICO
(or PICOTS: Population, Intervention, Comparator, Outcome,
Time and Setting) methodology [36] (which is also applied, but
non-explicitly, in the CHEERS explanation). The “question fram-
ing” part, although not necessarily specific to OA studies, is
crucially important. Risk profiling should be used in order to
identify how similar patients are within the study popula-
tion and for identifying subgroups of interest. An important
process for researchers performing meta-analyses and indirect
(network) comparisons is the description and categorisation of
the important outcome from patients' viewpoint (those that are
critical, important or of limited importance). As stated in the
CHEERS explanation, the decisional question (and whether the
research was conducted for a decision maker) should be
detailed.
Table 1
Set of disease-specific recommendations on the conduct and reporting of economic evaluations in osteoarthritis (presented in the format of the CHEERS statement)
Section Item Standard CHEERS description Specificity for economic evaluations in OA
Title and abstract 1 Identify the study as an economic evaluation, or use more specific
terms such as “cost-effectiveness analysis” and describe the
interventions compared.
Provide a structured summary of objectives, perspective, setting,
methods (including study design and inputs), results (including
base case and uncertainty analyses), and conclusions
Introduction
Background and
objectives
2 Provide an explicit statement of the broader context for the study.
Present the study question and its relevance for health policy or
practice decisions
Frame the research question using evidence-based practice
methodology, e.g., the GRADE 2 guideline: Framing the question
and deciding on important outcomes and using the Population,
Intervention, Comparator and Outcome (PICO) process.
Methods
Study design/model
structure
3 [New item incorporating aspects of items 11 and 15] Describe the basic design of the study or model structure (see
items 11 and 15) to help frame the subsequent description of
methods.
Target population
and subgroups
4 Describe characteristics of the base case population and subgroups
analysed including why they were chosen
Three separate reference cases for OA are proposed, hand, knee or
hip, in patients seeking medical advice for a painful joint
affected by OA (the ACR criteria). Variants on each reference case
may be considered: e.g., interphalangeal or thumb-based
complaints for hand OA; the presence of clinically important
malalignment for knee OA and severe disease with persistent
pain and marked disability.
Subgroups of interest might include age, gender and BMI, also
comorbidity factors (e.g., GI or CV risk).
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need
(s) to be made
Study perspective 6 Describe the perspective of the study and relate this to the costs
being evaluated
If no specific official/national guideline/decision making context
needs be followed, then a broad perspective (“societal”),
including a wide range of costs and benefits, falling on the
healthcare system, patients and broader economy, is preferred.
Comparators 7 Describe the interventions or strategies being compared and state
why they were chosen
The most appropriate comparators will depend on the reference
case considered (the hand, knee or hip). Ideally, one comparator
would be “standard optimal care.”
Time horizon 8 State the time horizon(s) over which costs and consequences are
being evaluated and say why appropriate
Since OA is a chronic disease, the application of a lifetime horizon
is encouraged. For comparative studies in pain control, shorter
horizons are acceptable.
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes
and say why appropriate
Choice of health
outcomes
10 Describe what outcomes were used as the measure(s) of benefit in
the economic evaluation and their relevance for the type of
analysis performed
The QALY has been endorsed by OMERACT and ESCEO for use in
musculoskeletal studies.
Measurement of
clinical
effectiveness or
harm
11a Single study-based estimates: Describe fully the design features of
the single effectiveness study and why the single study was a
sufficient source of clinical effectiveness data
The effect of treatment should be assessed on the core set
outcomes for rheumatology studies (pain, functional ability
[using a validated disease-specific QoL instrument] and patient
global assessment [PGA]). Adverse events should be reported
using the OMERACT common toxicity criteria.
11b Synthesis-based estimates: Describe fully the methods used for the
identification of included studies and synthesis of clinical
effectiveness data
Relevant outcome measures should be selected using the GRADE
system.
Measurement and
valuation of
preference-based
outcomes
12 If applicable, describe the population and methods used to elicit
preferences for outcomes
The EQ-5D is the preferred indirect (multiattribute) utility
estimator (although SF-6D and HUI-2 or -3 can also be used).
The score from the disease-specific QoL instrument should also
be converted to a utility score for use in a sensitivity analysis.
Estimating resources
and costs
13a Single study-based economic evaluation: Describe approaches used
to estimate resource use associated with the alternative
interventions. Describe primary or secondary research methods
for valuing each resource item in terms of its unit cost. Describe
any adjustments made to approximate to opportunity costs
A process-based categorisation of resources and costs into
predefined domains is recommended, with use (where possible)
of national standardised lists of costs for valuation.
13b Model-based economic evaluation: Describe approaches and data
sources used to estimate resource use associated with model
health states. Describe primary or secondary research methods for
valuing each resource item in terms of its unit cost. Describe any
adjustments made to approximate to opportunity costs
Currency, price date
and conversion
14 Report the dates of the estimated resource quantities and unit costs.
Describe methods for adjusting estimated unit costs to the year of
reported costs if necessary. Describe methods for converting costs
into a common currency base and the exchange rate
Choice of model 15 Describe and give reasons for the specific type of decision-analytic
model used. Providing a figure to show model structure is strongly
recommended
Assumptions 16 Describe all structural or other assumptions underpinning the
decision-analytic model
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Table 1 (continued )
Section Item Standard CHEERS description Specificity for economic evaluations in OA
Analytic methods 17 Describe all analytic methods supporting the evaluation. This could
include methods for dealing with skewed, missing, or censored
data; extrapolation methods; methods for pooling data;
approaches to validate or make adjustments (e.g., half-cycle
corrections) to a model; and methods for handling population
heterogeneity and uncertainty
Results
Study parameters 18 Report the values, ranges, references, and if used, probability
distributions for all parameters. Report reasons or sources for
distributions used to represent uncertainty where appropriate.
Providing a table to show the input values is strongly
recommended
Incremental costs
and outcomes
19 For each intervention, report mean values for the main categories of
estimated costs and outcomes of interest, as well as mean
differences between the comparator groups. If applicable, report
incremental cost-effectiveness ratios (ICERs)
Characterising
uncertainty
20a Single study-based economic evaluation: Describe the effects of
sampling uncertainty for estimated incremental cost, incremental
effectiveness, and incremental cost-effectiveness, together with
the impact of methodological assumptions (such as discount rate,
study perspective)
20b Model-based economic evaluation: Describe the effects on the
results of uncertainty for all input parameters, and uncertainty
related to the structure of the model and assumptions
Characterising
heterogeneity
21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between
subgroups of patients with different baseline characteristics or
other observed variability in effects that are not reducible by more
information
Discussion 22 Summarise key study findings and describe how they support the
conclusions reached. Discuss limitations and the generalisability of
the findings and how the findings fit with current knowledge
ACR: American College of Rheumatology; BMI: body mass index; CV: cardiovascular; GI: gastrointestinal.
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New item incorporating aspects of items 11 and 15.
Modification for economic evaluations in general: Describe the
basic design of the study or model structure (see items 11 and 15)
to help frame the subsequent description of methods.
Examples: Study design in comparative clinical studies: “This economic evaluation was a retrospective longitudinal
cohort study using data from the GPRD.” “An economic evaluation was conducted alongside a cluster
randomised controlled trial comparing behavioural graded
activity and usual care according to…”
Model Structure (as outlined in item 15 of CHEERS): “A decision analytic model was developed comparing the
decision options and reflecting the clinical events in terms of
their probabilities of taking place and the consequences in
terms of costs and utilities…” “The disease process was formulated as a transition through a
series of health states, modelled using a Markov approach”
Explanation: It was considered particularly helpful if the main
features of the study design or model structure are described in
the first paragraph of the methods section. Thus, the design of the
study should be outlined, e.g., whether it was an RCT or pragmatic
design or if it was a data extraction from a general practice
database or a mathematical model synthesising data from several
sources including meta-analyses. As stated in item 11 of CHEERS,
attention should be paid to fulfilling other applicable reporting
requirements (CONSORT for RCTs and pragmatic designs [32,37];STROBE for observational designs [38] and PRISMA for meta-
analyses [39]). Although the use of a single RCT as a data source
for economic analysis may be questionable [40], the data obtained
from such studies can be instructive on an initial basis for decision
making especially during early clinical drug development. If the
analysis concerns modelling of economic data, then the model
structure, as outlined in item 15 of CHEERS, should be detailed,
taking account of existing good practice guidelines [41,42].
Target population and subgroups (item no. 4)
CHEERS describe characteristics of the base case population and
subgroups analysed including why they were chosen.
Extension for economic evaluations in OA: Three separate refer-
ence cases for OA are proposed, the hand, knee or hip, in patients
seeking medical advice for a painful joint affected by OA (the
American College of Rheumatology criteria). Variants on each case
may be considered: e.g., interphalangeal or thumb-based com-
plaints for hand OA, and the presence of clinically important
malalignment for knee OA, and severe disease with persistent
pain and marked disability. Subgroups of interest might include
age, gender and body mass index, including comorbidity factors
(e.g., gastrointestinal or cardiovascular risk).
Explanation: The working group proposes the following three
distinct reference cases: patients seeking medical advice for a
painful joint affected by OA in the (i) hand, (ii) knee or (iii) hip. In
each, the clinical diagnosis should fulfil the current American
College of Rheumatology (ACR) classification criteria for OA
[43,44]. Variants on the reference case could be envisaged to
encompass different presentations of the disease, e.g., interpha-
langeal or thumb-based complaints for hand OA and the presence
of any clinically important malalignment for knee OA.
Table 2
Proposals for intervention comparators according to OA reference case
Reference
case
Comparator possibilities according to reference case variants
Hand Interphalangeal disease: Topical capsaicin vs. topical NSAID gel
(e.g., diclofenac gel)
Thumb-based disease: Intra-articular (IA) glucocorticoids vs. IA
hyaluronate (with or without splinting)
Knee Non-pharmacologic interventions:
Nutritional counselling for weight loss vs. the same plus
exercise (either aerobic or resistance)
In patients with malalignment: Bracing vs. osteotomy
Pharmacologic interventions:
Glucosamine sulphate vs. chondroitin sulphate vs. both vs. oral
paracetamol vs. oral NSAIDs
IA glucocorticoids vs. hyaluronate in patients with an
inadequate response to either paracetamol or NSAIDs
Hip IA glucocorticoids vs. hyaluronate in patients with an inadequate
response to either paracetamol or NSAIDs
NSAIDs: Non-steroidal anti-inflammatory drugs.
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to our understanding of the natural history of OA [25,45–49] and
brought out the differences between these disease conditions in
terms of prevalence and risk factors (both intrinsic and extrinsic)
and the medical impact at a level of functional independence and
all-cause mortality. Furthermore, it is now clear that biomechan-
ical changes in the joint have a strong influence on progression,
hence the need to consider varus/valgus deformity separately [50].
Other variants should be considered for patients having severe
knee or hip OA, which are characterised by persistent pain and
marked disability. The subsequent step for these individuals would
be elective joint replacement.
Subgroups of interest might be defined along demographic
criteria, such as age and gender or according to comorbidity
factors, including obesity or risks relating to gastrointestinal or
cardiovascular events. It might be useful to add a measure of
comorbidity [51] since this as well as health-related quality of life
(QoL) are powerful predictors of health care outcomes and costs
[47,52,53].
Study perspective (item no. 6)
CHEERS describe the perspective of the study and relate this to
the costs being evaluated.
Extension for economic evaluations in OA: If no specific official/
national guideline/decision-making context needs be followed,
then a broad perspective (“societal”), including a wide range of
costs and benefits, falling on the health care system, patients and
broader economy, is preferred.
Explanation: If the main objective of the analysis is regulatory,
then the guidelines of the competent national authority (e.g.,
UK's National Institute for Health and Care Excellence (NICE) or
the Canadian Agency for Drugs and Technologies in Health; see
www.ispor.org for worldwide directory of Health Technology
Assessment bodies) need to be followed (e.g., the decision maker's
perspective, specific health care provider or third party payer). If
this is not the case, then because of the chronic nature of OA and
its impact on productivity costs, the broad perspective is preferred.
Comparators (item no. 7)
CHEERS describe the interventions or strategies being com-
pared and state why they were chosen.
Extension for economic evaluations in OA: The most appropriate
comparators will depend on the reference case considered (the
hand, knee or hip). Ideally, one comparator would be “standard
optimal care.”
Explanation: Recommendations and guidelines on the manage-
ment of OA have been published by learned bodies on several
occasions over the last 15 years; notable are the recommendations
by the European League Against Rheumatism (EULAR) for knee
(2003), hip (2005) and hand (2007) OA [6–8], those of the
Osteoarthritis Research Society International (OARSI) for hip and
knee (2008) OA, updated in 2010 [9,11], and the guidelines by NICE
(2008) [10] and the American College of Rheumatology (ACR;
2012) for hand, hip and knee OA [12]. These have generally used a
Delphi process, or other voting systems, to find a consensus
amongst invited experts for the various therapeutic strategies
proposed.
The recommendation is to first select one of the three reference
cases in OA and then consider the most appropriate comparators.
Table 2 lists some suggested comparators for each of the proposed
reference cases. Since our knowledge is still imperfect, a single
“standard optimal care” proposal for each condition is not possible
at this time. The table provides the most plausible options, but
these should be empirically tested head-to-head before we can bemore certain of the “standard” treatment. Until that time, it would
be supportive if researchers used at least one of the proposed
options in their study design.
All guidelines have underlined the diversity of the OA condition
and noted that optimal management needs a combination of non-
pharmacological and pharmacological treatment modalities that
are individualised to the patient's requirements.
Hand OA
For the management of symptomatic interphalangeal OA, the
preferred pharmacological approach is a local treatment; either
topical NSAID (such as diclofenac gel) or topical capsaicin cream.
Both have shown superior pain relief in placebo-controlled studies
(see recommendations for references), but there are relatively few
high-quality RCTs of interventions for hand OA published in the
peer-reviewed literature. It has been shown that topical NSAIDs are
associated with fewer GI adverse events than oral NSAIDs [54]. An
economic model should be constructed to reflect the use of treat-
ments based on the existing data of efficacy and the side-effects.
For the management of symptomatic thumb-based OA (i.e., OA
of the trapeziometacarpal joint) the usual initial therapeutic
approach is splinting [8,12], although the evidence for this is
based mainly on expert opinion. Pain relief for these patients is
oral paracetamol first line (up to 3 g/day), then oral NSAIDs second
line (at the lowest dose and for the shortest duration possible) [8].
For patients who do not respond to this, the next course of action
is usually intra-articular glucocorticoids or hyaluronates (although
the latter is not licensed for hand OA in all countries) [12].
A factorial study design, including/excluding splinting, with phar-
maceutical therapy might add considerably to our clinical
knowledge.
Knee OA
In the management of patients with symptomatic knee OA, the
first step is an attempt to correct any tendency towards over-
weight by prescribing a weight loss programme, usually with a
physical exercise programme [55]. The recently published results
of the IDEA trial [56] showed that weight loss, in obese/overweight
patients, in combination with a physical exercise programme
produced the best results in terms of reduction of knee joint
compressive force, inflammatory biomarkers and pain vs. either
the weight loss alone or the physical exercise alone. There is also
strong agreement that, irrespective of bodyweight, the manage-
ment of OA should include weight-bearing physical activity [57].
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weight loss and exercise programmes, but the differences in
design and outcome measures so far preclude any straightforward
comparisons [14]. Non-adherence to these programmes is also a
big problem and these dropout rates vary widely according to the
programme. This issue needs to be addressed by well-designed
observational studies having suitable accepted end point(s) and
long-term follow-up. Subsequently, modelling studies need to be
done to test the impact of realistic, and potentially different,
dropout rates.
In patients with varus (or valgus) malalignment, an important
therapeutic choice is correction by bracing or osteotomy. In open-
label cohort studies, bracing has shown some efficacy in reducing
pain and function, but the design of these economic evaluations
suffer in the absence of a comparison group (generally they receive
physical therapy or static bracing). Valgus osteotomy improves
knee function and reduces pain, but there is no evidence whether
osteotomy is more effective than conservative treatment [58].
Short-term data also exists from case series, and some long-term
data suggest that bracing may delay the need for total joint
arthroplasty [59].
Hip OA
For the management of symptomatic hip OA, the clinical
evidence supports the use of intra-articular injections of cortico-
steroids or hyaluronates (although the latter is not licensed for hip
OA in all countries). The cost-effectiveness of these two pharma-
cological treatments needs to be compared. There is very limited
evidence of any effective non-pharmacological modalities
(e.g., exercise programmes). Curiously, while high body mass index
(BMI) was found to be significantly associated with knee OA and
hand OA, it did not seem to be correlated with the incidence of
hip OA [60].
Further considerations for each reference case. It is important to dis-
tinguish between a single management strategy and a combination
of pharmaceutical and non-pharmacological strategies, especially
since it is recognised that optimal management often requires a
combination of these two strategies. In the absence of direct (head-
to-head) comparisons, estimates of effectiveness can be obtained
from indirect methods based on a systematic review or network
meta-analysis, as recently demonstrated for exercise interventions in
patients with lower limb arthritis [61].
Total joint replacement. The option of major surgery as a com-
parator could theoretically be envisaged to evaluate surgery-
sparing treatments, but consensus will be required to define a
surrogate end point of “time to treatment failure” or “need for
joint replacement surgery.” Previous attempts to define such an
end point [62,63] have not been conclusive. This clinical end point
would also be a useful starting point for economic evaluations of
treatment and rehabilitation strategies. The comparative effective-
ness of joint replacement has been modelled for various
scenarios, for example, different prostheses types in total hip
replacement [64] and simultaneous vs. staged bilateral total knee
arthroplasty [65].
Time horizon (item no. 8)
State the time horizon(s) over which costs and consequences
are being evaluated and say why appropriate.
Extension for economic evaluations in OA: Since OA is a chronic
disease, a lifetime horizon is most often appropriate. However, for
comparative studies in pain control, shorter horizons are accept-
able.Explanation: Ideally, the time horizon for economic modelling
in OA should be lifetime, as for other chronic diseases such as
osteoporosis. If the data limitations make this difficult, then
analyses should cover the longest time span possible. For the
cost-effectiveness of NSAIDs, de Groot et al. [66] modelled over a
5-year horizon, which seems reasonable in their model that
encompassed various gastrointestinal-related health states but
no progression of the OA.
A common complaint of both clinical systematic reviewers and
economic modellers is that the treatment durations of clinical
studies in OA are frequently too short to fully assess all relevant
outcomes that might be useful in a thorough economic evaluation;
but such are the limitations in the face of the budgetary con-
straints. Modelling beyond the trial duration therefore demands a
number of assumptions of continued treatment benefits, risks and
adherence. These uncertainties multiply when the horizon of the
model is widely different from that of the source data, and the use
of long-term observational data may help to position intermediate
to long-term outcomes. It is accepted, however, that models are by
nature exploratory and, if well-constructed, provide valuable
predictive information [67] or inform as to what essential data
are lacking in a decision-making context [68].
Choice of health outcomes (item no. 10)
CHEERS describe what outcomes were used as the measure
(s) of benefit in the economic evaluation and their relevance for
the type of analysis performed.
Extension for economic evaluations in OA: The QALY has been
endorsed by OMERACT and ESCEO for use in musculoskeletal
studies.
Explanation: The application of cost–utility analysis is recom-
mended in OA and the use of the QALY was endorsed by the 2011
OMERACT economics working group for economic studies in
musculoskeletal diseases [69]. The QALY is the common metric
used by most national review agencies and its use in OA was
endorsed by the ESCEO group.
Measurement of clinical effectiveness or harms (item no. 11)
Item no. 11a
Single study-based estimates: Describe fully the design features
of the single effectiveness study and why the single study was a
sufficient source of clinical effectiveness data.
Extension for economic evaluations in OA: The effect of treatment
should be assessed on the OMERACT core domains of outcomes in
rheumatology {pain, functional ability [using a validated disease-
specific Quality of Life (QoL) instrument] and patient global
assessment [PGA]}. Adverse events should be reported using the
OMERACT common toxicity criteria.
Explanation: The core set of outcome domains and measures for
phase III clinical trials in hip, knee or hand OA was established by
the OMERACT III conference [70] as being pain reduction, improve-
ment/preservation of functional ability, PGA and, for studies of
1 year or longer, structural damage as evidenced by joint imaging.
To this list should be added the reporting of the incidence and
seriousness of adverse events. The perimeter of the core outcome
set has been extended slightly by the OMERACT 2.0 filter [71] and
further consensus is required.
Pain. Pain intensity in the target joint should be measured using a
validated self-assessment method, such as a generic visual
analogue scale (VAS) or a numeric rating scale (NRS or Likert
scale) using verbal pain intensity descriptors (preferably 7 or 11
points) [72]. There is a growing trend towards the use of NRS, since
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Apart from these simple scales, a wide variety of outcome
measures have been employed to assess pain [73] and there
appears to be little consensus as to the best method. The
following two distinct pain types have been identified in patients
with OA: an intermittent intense pain (often with an unpredictable
onset) and a dull, aching pain [74], and these are probably in some
way related to the multifactorial aetiology of the disease [75]. In
the past, the pain experience has also been captured by the various
disease-specific QoL tools such as the Michigan Hand Outcomes
Questionnaire (MHQ; [76]), the Oxford Hip and Knee Scores (OHS
and OKS [77]), the Hip and Knee Osteoarthritis Outcome Scores
(HOOS and KOOS [78,79]) or the Western Ontario and McMaster
Universities score (WOMAC; for knee or hip [80]). It is likely,
however, that these instruments distort the reporting of pain since
the questions are embedded in a framework of physical
functioning [74]. The Intermittent and Constant Osteoarthritis
Pain (ICOAP) questionnaire was developed more recently to try
to capture the distinct pain types in OA [81].
Functional ability. This is usually assessed by one of the well-known
disease-specific tools cited above, as well as others such as the
Arthritis Impact Measurement Scale 2 (AIMS2 and AIMS2-SF [82]),
the Functional Index for Hand OA (FIHOA [83]) or the Lequesne
Algofunctional Index [84] or the generic, Health Assessment
Questionnaire-Disability Index (HAQ-DI [85]). At least 158 different
self-reported measures of OA burden have been published and
amongst these, the representation of various aspects of OA burden
is quite heterogeneous [86]. It is now accepted that emphasis of end
point assessment should be preferably on patient-reported
outcomes (thus diminishing the role of some of the scales above).
While previous OARSI recommendations have highlighted the need
to evaluate changes in OA-related fatigue, poor sleep, depressed and
anxious mood and participation in valued activities, [50] there
appears to be no consensus as to the most suitable instrument.
The need for a different outcome assessment process following joint
replacement is unlikely [87].
With the development of computerised adaptive testing, using
item response theory, it is expected that new outcome instruments
will appear that will alleviate the burden of questions and yet
retain high degrees of accuracy and statistical power [88]. The
FDA's PROMIS initiative (Patient-Reported Outcomes Measurement
Information System) is of interest in this respect, since plans are to
build a modular set of validated and standardised item banks
ready for use in adaptive conditions [89]. It also embraces the
language and concepts of the International Classification of Func-
tioning, Disability and Health (ICF) framework of the World Health
Organization (WHO), which was recently recognised by OMERACT
in their 2.0 filter for core outcome measurement sets [71,90].
The patient global assessment. PGA asks a patient to rate on a scale
how they feel overall by indicating the result on a VAS or using
descriptors such as “well” or “poor.” This simple assessment has
relative high retest validity.
Adverse events. Standardised reporting using common toxicity
criteria (as proposed by the OMERACT toxicity working group) is
advocated [91] and the decision should be made if any specific
adverse events need to be considered in detail. It is important that
any adverse effects are accurately captured by the QoL measure.
Not often measured as an outcome parameter, given the relatively
short duration of most clinical studies, mortality data should be
obtained in retrospective observational studies and, separated
where possible into OA-related death and non-related, used to
populate models having lifetime horizons.There are no validated surrogate end points in OA. Proposed
definitions of “time to treatment failure” or “need for joint
replacement surgery” based on the structural changes and symp-
tomatic thresholds have been made; however, a convincing
algorithm that combines the various components has yet to be
found [63]. A validated surrogate end point could prove critical for
the development of DMOADs, since their economic attractiveness
will be in delaying this end point. A related and important
question will be to test if delaying the time to arthroplasty
compromises the success of this intervention.Item no. 11b
Synthesis-based estimates: Describe fully the methods used for
the identification of included studies and synthesis of clinical
effectiveness data.
Extension for economic evaluations in OA: Relevant outcome
measures should be selected using the GRADE system.
Explanation: In the situation where the studies in the field have
used a wide variety of outcome measures, it is suggested that the
GRADE guideline 2 (mentioned previously) approach might be
used to classify them and select the relevant one according to
the perspective of the analysis. Clearly, the priority would go to the
outcome measures listed in the previous section, but in the
necessity to maximise the collection of information, other meas-
ures might be considered.Measurement of and valuation of preference-based outcomes
(item no. 12)
CHEERS if applicable, describe the population and methods
used to elicit preferences for outcomes.
Extension for economic evaluations in OA: The EQ-5D is the
preferred indirect (multiattribute) utility estimator (although
SF-6D and HUI-2 or -3 can also be used). The score from a relevant
disease-specific QoL instrument could also be converted to a utility
score for use in a sensitivity analysis.
Explanation: The use of indirect utility measures, such as the
EuroQoL-5D (EQ-5D), is preferred rather than more challenging
and time-consuming methods that centre on risk and choice
(e.g., chance of improvement and willingness to pay) [69,92].
Other indirect utility estimators may also be suitable, such as the
Medical Outcomes Study Short-Form 6D (SF-6D) and the Health
Utility Index (HUI, version 2 or 3); however, concern has been
raised that systematic differences can be seen between EQ-5D and
SF-6D scores [93,94]. Direct measures of patient preference can
provide a valuable addition to the knowledge base, but it is
cautioned that willingness-to-pay values appear to reflect the
socioeconomic status of patients more than the clinical status [95].
Using mapping algorithms, the scores from a disease-specific
QoL instrument can be converted to utility scores and therefore
provide valuable data for sensitivity analyses. Attention should be
paid, however, to the most valid mapping method and the choice
of algorithm should be justified [69,96]. This method of obtaining
utility values should not be preferred over the generic instrument
[97,98].Estimating resources and costs (item no. 13)
Item no. 13a
Single study-based economic evaluation: Describe approaches
used to estimate resource use associated with the alternative
interventions. Describe primary or secondary research methods
for valuing each resource item in terms of its unit cost. Describe
any adjustments made to approximate to opportunity costs.
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categorisation of resources and costs into predefined domains is
recommended, with use (where possible) of national standardised
lists of costs for valuation.
Explanation: It is recommended that the costing process should
be considered in stages. Mittendorf et al. [99] provide a flow
diagram with a proposed process. The ESCEO group felt the need
to highlight just two stages: Identifying the resources incurred for delivering the strategies
compared (which should be the same across different countries
for any given strategy). Resource use should be collected for all
relevant domains including not only those associated with the
intervention but also related primary and secondary care
resources, as well as treatments that may not necessarily be
“disease-specific.” Resource use should be considered with
regard to the perspective of the analysis. Attributing costs to these resources according to the perspec-
tive defined in the objectives of the research (which is likely to
vary between different countries due to the specificities of the
health care systems). Where possible, national standardised
lists of costs should be used for medical procedures and
treatments (available for instance in the Netherlands and
currently being developed for several other countries). Treat-
ment tariffs, on the other hand, can be misleading, in that they
may not account for the resources actually used. For studies
that are conducted internationally, difficulties can arise where
certain cost items might be considered as direct in some
countries, but indirect in others (i.e., another reason to canvas
for a societal perspective).
It is justified to focus on the more frequent and significant
resource utilisation rather than on rare items (unless the costs of
these rare items are very high). Particular care should be paid to
the collection of outpatient costs, since these are frequently long-
term and borne by diverse payers. A comparison of “disease-
specific” resource use may be considered in a form of sensitivity
analysis with all costs as the base case scenario.
If a broad perspective is used for the analysis, then indirect
costs should be attributed. In this domain, one of the more
“difficult” costs to estimate is that of lost productivity. Most often,
this is valued using the human capital approach (i.e., a method of
lifelong salary conversion) or the friction-cost method (taking into
account replacement by unemployed) [100]. Difficulty arises not
only in the choice of method but also in the use of the patients'
estimations of their own absenteeism. Compensation mechanisms
for sick employees vary significantly between countries and,
where present, they may lead to an overestimation of costs
[101]. An alternative and perhaps more suitable approach to lost
productivity is the introspective or “firm-level” method (i.e., what
is the cost to the company to replace the incapacitated employee)
[102]. Also difficult is attributing cost to “presenteeism” (i.e., the
person is present at work but unable to fulfil his/her job descrip-
tion due to arthritis pain) since there is insufficient evidence if
there is real lost productivity or if there is compensatory assistance
from other workers [103]. Still, methods are being developed and
in the process of being validated.Discussion
This proposition for a reference case (or reference cases) in OA
for the conduct of economic studies follows the path started by
OMERACT a number of years ago in its efforts to standardise
clinical research in rheumatic diseases. The objective then, as now,
was to improve the consistency of methodological approach so asto allow more meaningful comparisons between studies, with a
goal of elaborating a limited number of OA models that are
suitably flexible to adapt to the clinical situation and easy to use
for economic evaluations. Available with open access, these
models would be regularly updated with new information and
available to perform for new strategies or technologies. As a
platform on which to present the current recommendations in
OA, the ESCEO working group chose to use the recently published
CHEERS statement (a list of items to be included in the reporting of
economic evaluations); thus, combining recommendations for
study conduct with those for study reporting.
Eight of the items in CHEERS, judged to be most sensitive to
disease-specific choices, were given additional text to explain the
situation in OA. The main additions were to the items “target
populations and subgroups” and “comparators,” for which the
working group recommends the distinction of three reference
cases in OA, the hand, knee or hip (and/or a variant according to
presentation or severity), and an associated choice of treatment
strategy. Another important disease-specific item was that of
outcome measures that should be used to evaluate and/or model
health over time, and for which the working group made recom-
mendations based on the OMERACT core set (pain intensity,
functional ability, PGA and adverse events). Utility scores should
be obtained using an indirect estimator (preferably EQ-5D) and,
secondarily, by mapping from a disease-specific tool. Finally, the
costing of treatment in OA should follow as closely as possible, a
process-based categorisation with use (where possible) of national
standardised lists of costs.
For each of these main disease-specific items, it remains clear
that significant gaps in our knowledge exist and that some of our
recommendations rest more on expert opinion than on evidence-
based medicine. The research agenda therefore remains long: Therapeutic strategies: the strategies outlined in the recommen-
dation could be used as acceptable comparators but, ideally,
further research is needed on head-to-head comparisons and
on the combinations or sequences of pharmacological and non-
pharmacological approaches. A key advance would be to find a
consensus for each reference case on the “standard optimal
care,” so that this treatment strategy might be used as one of
the comparator arms in any interventional study. Outcome measures: The best way to measure pain intensity and
functional ability in OA remains widely debated and a key
advance would be to find a consensus on their measurement
scale in OA. Questions persist as to the degree of acceptable
overlap in pain measurement with the assessment of functional
ability and whether there should be more investigation of pain
avoidance behaviours [104]. Similarly, for the assessment of
functional limitations, there are questions concerning the over-
lap of conceptual domains in the questions asked [105]. With
the two international initiatives that aim to improve the
quantification of the perceived impact of a health condition
on the individual, PROMIS and ICF framework, researchers have
begun to re-examine older instruments, and improved assess-
ment tools are to be expected [106,107]. Other questions arise
as to how to integrate the notion of responders into the
outcome measure [108,109] and responders with disease
severity. Recent OMERACT conferences have discussed the
usefulness of two new complementary metrics for treatment
response: the Minimally Clinically Important Improvement
(MCII) and the Patient Acceptable Symptom State (PASS)—both
of which appear relevant in daily clinical practice [110]. The
PASS, with its binary response to a simple question, correlates
pain intensity measures (NRS or VAS) well [110] and has also
been used to determine satisfaction after total joint replace-
ment [111].
M. Hiligsmann et al. / Seminars in Arthritis and Rheumatism 44 (2014) 271–282280 Utility scoring: The reasons that underlie the reported differ-
ences in utility scores between EQ-5D and SF-6D and perhaps
other measures [93,94] should be further investigated. It would
also be instructive to evaluate the differences between map-
ping techniques to converting disease-specific QoL tools to
utilities. A key advance would be to find a consensus on a default base
case lifetime model including, for each reference case, an
accommodation of the expected decline in QoL with increasing
age [112]. Comorbidity is a major factor in these patients, and
with the OA-related decrease in mobility, other chronic medical
conditions then tend to accumulate. OA and depression are
associated with the strongest depression of EQ-5D index scores
[113]. Although the rates of chronic disability in the USA seem
to have declined in recent years, it remains to be seen if this
will be counteracted by increases in obesity prevalence [114]. In
general, the valuing of health states for cost-effectiveness
analysis remains a major concern [115]. Resource utilisation: The allocation of costs in OA poses numer-
ous challenges, especially in the situation of international
comparisons or clinical trials. The provision of health care in
terms of access to treatment and reimbursement varies widely
in different countries even amongst those of the European Union
[116]. Between-country differences also exist in mechanisms of
compensation for absenteeism with the result that data on
productivity loss may be more or less comparable according to
the context [101]. Other questions to be resolved include
whether social security benefits should be included in the
analysis as transfer costs or omitted from costing and should
health benefits be discounted at the same rate as costs [117].
The recently developed OMERACT filter 2.0 proposes a frame-
work to define (and obtain consensus on) core outcome measure-
ment sets for different health conditions [71]. It proposes a broad
notion of outcome, that of the impact of the disease: death (either
all-cause death or due to the intervention under study), life impact
(health-related QoL including pain and functional indices) and
resource use (i.e., economic impact), and a fourth area (outside of
“impact”) called the “pathophysiological manifestations of health
conditions,” which concerns other aspects of the target organ
biology (such as biomarkers and surrogate outcomes, but also
including psychosocial manifestations). Thus, if one were to
develop, for OA, a core set based upon this framework, one should
add the following to the research agenda presented above:
a consensus on the definition of OA-related deaths (and it is
known that patients with OA are at a higher risk of death
compared with the general population [47]), what pathophysio-
logical manifestations of OA should be included in the outcome
measure among the promising biomarker candidates [118,119] and
can a consensus be obtained on a definition of relevant radiological
progression in OA [120]. With regard to economic evaluations, it
should be explored to what extent these variables help define
relevant subgroups for OA management (perhaps also helping to
better understand the pain experience and effects of innovative
treatments).Conclusion
A number of specific recommendations are proposed concerning
the conduct of economic evaluations in OA that we believe could
help the standardisation and comparability of research in this area.
Further refinement is still required, and it is anticipated that some
of the remaining questions might be settled by launching a
consultation with a Delphi-type voting process. While reference
case recommendations should describe basic good practice incost-effectiveness research, these do not necessarily imply consen-
sus [17,18], since the idea is to create a tool to facilitate comparisons.
However, it is clear that adherence to any proposition would be
more likely if the consensus view were taken. It would be
a considerable advance if a consensus could be found on the
“standard optimal care” for each reference case, so that this treat-
ment strategy might be used as one of the comparator arms in any
interventional study. Also helpful would be a consensus on the core
outcome measures, since just this step alone has the potential to
improve the health care evidence base [121].Acknowledgements
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